Dyadic International, Inc. – NASDAQ:DYAI
Founder-led company
Dyadic International stock price today
$0.79
-1.16
-59.68%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 12 hours
Dyadic International stock price monthly change
+31.54%
month
Dyadic International stock price quarterly change
+31.54%
quarter
Dyadic International stock price yearly change
+23.27%
year
Dyadic International key metrics
Market Cap | 54.14M |
Enterprise value | N/A |
P/E | -5.19 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 12.85 |
Price/Book | 4.91 |
PEG ratio | -0.18 |
EPS | -0.27 |
Revenue | 2.25M |
EBITDA | -8.24M |
Income | -7.84M |
Revenue Q/Q | -65.78% |
Revenue Y/Y | -30.81% |
Profit margin | -366.15% |
Oper. margin | -382.99% |
Gross margin | 30.64% |
EBIT margin | -382.99% |
EBITDA margin | -365.59% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeDyadic International stock price history
Dyadic International stock forecast
Dyadic International financial statements
| Jun 2023 | 837.15K | -2.15M | -257.17% |
|---|---|---|---|
| Sep 2023 | 397.06K | -1.61M | -406.55% |
| Dec 2023 | 686.53K | -2.07M | -301.78% |
| Mar 2024 | 334.61K | -2.00M | -600.57% |
| 2025 | 6.1M | -11.3M | -185.25% |
|---|---|---|---|
| 2026 | 5.5M | -11.1M | -201.82% |
Analysts Price target
Financials & Ratios estimates
| 2022-08-10 | -0.16 | -0.12 |
|---|---|---|
| 2022-11-10 | -0.0379 | -0.06 |
| 2023-03-29 | -0.05765 | -0.07 |
| 2023-05-10 | -0.07 | -0.15 |
| Jun 2023 | 11074540 | 2.08M | 18.86% |
|---|---|---|---|
| Sep 2023 | 9255566 | 1.60M | 17.32% |
| Dec 2023 | 8219236 | 2.34M | 28.48% |
| Mar 2024 | 12681266 | 8.16M | 64.39% |
| Jun 2023 | -1.65M | 1.12M | 0 |
|---|---|---|---|
| Sep 2023 | -1.96M | 3.52M | 0 |
| Dec 2023 | -923.38K | 34.15K | 0 |
| Mar 2024 | -1.11M | -654.90K | 5.82M |
Dyadic International alternative data
| Aug 2023 | 7 |
|---|---|
| Sep 2023 | 7 |
| Oct 2023 | 7 |
| Nov 2023 | 7 |
| Dec 2023 | 7 |
| Jan 2024 | 7 |
| Feb 2024 | 7 |
| Mar 2024 | 7 |
| Apr 2024 | 7 |
| May 2024 | 7 |
| Jun 2024 | 7 |
| Jul 2024 | 7 |
Dyadic International other data
7.63%
-8.51%
of DYAI is owned by hedge funds
17
-13
2.12M
-2.36M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2021 | 0 | 150000 |
| Dec 2021 | 0 | 90902 |
| Jul 2022 | 0 | 8943 |
| Patent |
|---|
Application Filling date: 9 Aug 2018 Issue date: 9 Jul 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 28 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 9 Aug 2023 | Q2 2023 Earnings Call Transcript |
-
What's the price of Dyadic International stock today?
One share of Dyadic International stock can currently be purchased for approximately $0.79.
-
When is Dyadic International's next earnings date?
Unfortunately, Dyadic International's (DYAI) next earnings date is currently unknown.
-
Does Dyadic International pay dividends?
No, Dyadic International does not pay dividends.
-
How much money does Dyadic International make?
Dyadic International has a market capitalization of 54.14M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 1.07% to 2.9M US dollars. Dyadic International made a loss 6.8M US dollars in net income (profit) last year or -$0.15 on an earnings per share basis.
-
What is Dyadic International's stock symbol?
Dyadic International, Inc. is traded on the NASDAQ under the ticker symbol "DYAI".
-
What is Dyadic International's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Dyadic International?
Shares of Dyadic International can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Dyadic International's key executives?
Dyadic International's management team includes the following people:
- Mr. Mark A. Emalfarb Founder, Chief Executive Officer, Pres & Director(age: 69, pay: $724,290)
- Mr. Matthew S. Jones Managing Director of Bus. Devel. & Licensing(age: 47, pay: $365,320)
- Ms. Ping Wang Rawson Chief Financial Officer(age: 49, pay: $301,090)
- Dr. Ronen Tchelet Vice President of Research & Bus. Devel.(age: 67, pay: $259,920)
-
Is Dyadic International founder-led company?
Yes, Dyadic International is a company led by its founder Mr. Mark A. Emalfarb.
-
How many employees does Dyadic International have?
As Jul 2024, Dyadic International employs 7 workers.
-
When Dyadic International went public?
Dyadic International, Inc. is publicly traded company for more then 17 years since IPO on 16 Jan 2008.
-
What is Dyadic International's official website?
The official website for Dyadic International is dyadic.com.
-
Where are Dyadic International's headquarters?
Dyadic International is headquartered at 140 Intracoastal Pointe Drive, Jupiter, FL.
-
How can i contact Dyadic International?
Dyadic International's mailing address is 140 Intracoastal Pointe Drive, Jupiter, FL and company can be reached via phone at +56 17438333.
Dyadic International company profile:
Dyadic International, Inc.
dyadic.comExchange:
NASDAQ
Full time employees:
7
Industry:
Biotechnology
Sector:
Healthcare
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
140 Intracoastal Pointe Drive
Jupiter, FL 33477-5094
Jupiter, FL 33477-5094
CIK: 0001213809
ISIN: US26745T1016
CUSIP: 26745T101
